MDR MedAdvisor

MedAdvisor to Expand into Hospitals as EBOS Invests $9.5M at $0.0575 Per Share

MELBOURNE, Australia--(BUSINESS WIRE)--

MedAdvisor (ASX:MDR), Australia’s leading digital medication management company, announces a $9.5 million strategic investment by one of Australasia’s leading healthcare companies, EBOS Group.

The investment is through a placement of approximately 165m ordinary shares in MedAdvisor at $0.0575 per share. EBOS has also purchased an additional 20 million shares in an off-market transaction.

EBOS becomes a substantial shareholder in MedAdvisor with a holding of just over 14%, alongside several other pharmacists and pharmacy groups who invested into MedAdvisor in prior capital raisings.

The investment will be used to extend MedAdvisor’s services to hospitals to help patients transition from hospital to home leveraging a new initial customer in HPS, to broaden the health services made available to pharmacies and their customers via MedAdvisor’s software, to increase the pace of international business development efforts in the UK and US and to extend those efforts to the Asia Pacific region, including New Zealand.

MedAdvisor and EBOS have signed 3 year in principal commercial agreements that expand the relationship with TerryWhite Chemmart and form a new relationships with each of HPS and Zest from EBOS’ Institutional Healthcare division. MedAdvisor estimates that over 3 years, these arrangements will generate ~$4m of revenue.

MedAdvisor will customise its app to be branded as TerryWhite Chemmart and include integrations with other TerryWhite Chemmart Loyalty Programs and offers.

MedAdvisor’s work in 2018 with HPS will result in simplification and improvement of hospital admission and discharge processes in HPS supported hospitals. It’s estimated that more than 5,000 patients a week will be invited to sign up to MedAdvisor, providing accurate medication information through the admission process and following their hospital stay, allowing an enhanced transition from hospital to home.

By working in collaboration with Zest, MedAdvisor will offer new services to hospitals to help prevent avoidable hospital readmissions and improve medication safety. These programs developed with Zest will include new services that can be provided to patients in MedAdvisor Pharmacies nationally.

EN
31/10/2017

Underlying

MDRMedAdvisor

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MedAdvisor

Free Trial
MDR MEDADVISOR

Medadvisor Limited: 1 director

A director at Medadvisor Limited sold 6,846,955 shares at 0.180AUD and the significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

11/10/23 November 10, 2023 1 EN
 PRESS RELEASE
Free
MDR MEDADVISOR

MedAdvisor to Expand into Hospitals as EBOS Invests $9.5M at $0.0575 ...

MELBOURNE, Australia--(BUSINESS WIRE)-- MedAdvisor (ASX:MDR), Australia’s leading digital medication management company, announces a $9.5 million strategic investment by one of Australasia’s leading healthcare companies, EBOS Group. The investment is through a placement of approximately 165m ordinary shares in MedAdvisor at $0.0575 per share. EBOS has also purchased an additional 20 million shares in an off-market transaction. EBOS becomes a substantial shareholder in MedAdvisor with a holding of just over 14%, along...

October 31, 2017 1 EN
EUR 18.48
MDR MEDADVISOR

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...

12/16/16 December 16, 2016 2 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch